secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2024-10-11T23:59:59+00:00
Accession:  0001193125-24-236468
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics reports Phase 1/2a data for [212Pb]VMT01; no dose-limiting toxicities observed
--------------------------------------------------------------------------------

- No dose-limiting toxicities; TEAEs mostly Grades 1–2; no renal toxicities reported despite high renal dosimetry.
- At 3.0 mCi dose: 1 RECIST objective response, 2 patients with stable disease at 9 and 11 months.
- At 5.0 mCi dose: patients progressed after first or second cycle; findings consistent with preclinical immunostimulatory effect at lower doses.
- SMC recommends testing 1.5 mCi dose as monotherapy and in combination with nivolumab; combination cohort now enrolling.
- Median 5 prior lines of therapy; FDA Fast Track Designation; plan to update on VMT-α-NET study by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000119312524236468/0001193125-24-236468-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000119312524236468/d871448d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-236468

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer